SAB Biotherapeutics (SABS) Shares Outstanding (Weighted Average) (2020 - 2026)

SAB Biotherapeutics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 476.42% year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at $53.6 million (up 476.42% YoY), and the FY2025 full-year result was $736337.0, down 92.05% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $53.6 million, up from $736337.0 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $53.6 million in Q1 2026, with the low at $575000.0 in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $15.1 million across 5 years, with a median of $9.2 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) plunged 88.31% — and 2026, when it soared 476.42%.
• SAB Biotherapeutics' Shares Outstanding (Weighted Average) stood at $736337.0 in 2022, then retreated by 21.91% to $575000.0 in 2023, then rose by 28.06% to $736337.0 in 2024, then changed by 0.0% to $736337.0 in 2025, then surged by 7173.66% to $53.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $53.6 million (Q1 2026), $736337.0 (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.